Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Single-arm, Open-Label, Multicenter Study Evaluating the Treatment Adherence, Tolerability, and Patient-Reported Outcomes of Giredestrant in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

NCT07827573 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07827573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07827573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Single-arm, Open-Label, Multicenter Study Evaluating the Treatment Adherence, Tolerability, and Patient-Reported Outcomes of Giredestrant in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
November 30, 2032
Enrollment
1,500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer, estrogen receptor-positive breast cancer, her2-negative breast cancer